Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 33
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Clin Infect Dis ; 76(5): 800-808, 2023 03 04.
Artículo en Inglés | MEDLINE | ID: mdl-36285530

RESUMEN

BACKGROUND: Primary immunodeficiencies (PIDs) in adults are mainly revealed by recurrent and/or severe bacterial infections. The objective of this study was to evaluate a systematic research strategy of PIDs in adults with unexplained bacterial infections, with a special focus on specific polysaccharide antibody deficiency (SPAD). METHODS: In this prospective multicenter study, inclusion criteria were recurrent benign upper and lower respiratory tract infections (RTIs) for at least two years (group 1), at least one upper or lower RTI requiring hospitalization (group 2), and/or at least one invasive infection documented with encapsulated bacteria (group 3). Main exclusion criteria were all local and general conditions that could explain infections. If no PID diagnosis was made, response to polysaccharide antigens was assessed using a pneumococcal polysaccharide vaccine. RESULTS: From March 2015 to March 2020, 118 patients were included (37 males, median age of 41 years): 73, 17, and 28 in groups 1, 2, and 3, respectively. Forty-seven PIDs were diagnosed, giving an estimated frequency of 39.8% (95% confidence interval [CI] [30.4, 48.8]). SPAD was the most frequent diagnosis by far (n = 37/47, 78.7%), and was made in 23, 5, and 9 patients from groups 1 to 3, respectively. All SPAD patients received conjugate vaccines and, according to their infectious history, were on surveillance or treated with preventive antibiotics (n = 6) and/or with immunoglobulins replacement therapy (n = 10), the latter being dramatically efficient in all cases. CONCLUSIONS: Considering its high prevalence among adults with unexplained recurrent and/or severe bacterial infections, SPAD should be screened in those patients. CLINICAL TRIALS REGISTRATION: NCT02972281.


Asunto(s)
Infecciones Bacterianas , Síndromes de Inmunodeficiencia , Infecciones Neumocócicas , Enfermedades de Inmunodeficiencia Primaria , Masculino , Humanos , Adulto , Estudios Prospectivos , Síndromes de Inmunodeficiencia/complicaciones , Síndromes de Inmunodeficiencia/epidemiología , Síndromes de Inmunodeficiencia/diagnóstico , Polisacáridos , Infecciones Bacterianas/epidemiología , Infecciones Bacterianas/tratamiento farmacológico , Enfermedades de Inmunodeficiencia Primaria/tratamiento farmacológico , Bacterias , Vacunas Neumococicas , Anticuerpos Antibacterianos , Infecciones Neumocócicas/prevención & control
2.
Eur J Clin Microbiol Infect Dis ; 42(1): 61-66, 2023 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-36376766

RESUMEN

We report in vivo development of cefiderocol (FDC) resistance among four sequential Pseudomonas aeruginosa clinical isolates ST244 recovered from a single patient, without exposure to FDC, which raises concern about the effectiveness of this novel drug. The first recovered P. aeruginosa isolate (P-01) was susceptible to FDC (2 µg/mL), albeit this MIC value was higher than that of a wild-type P. aeruginosa (0.12-0.25 µg/ml). The subsequent isolated strains (P-02, P-03, P-04) displayed increasing levels of FDC MICs (8, 16, and 64 µg/ml, respectively). Those isolates also showed variable and gradual increasing levels of resistance to most ß-lactams tested in this study. Surprisingly, no acquired ß-lactamase was identified in any of those isolates. Whole-genome sequence analysis suggested that this resistance was driven by multifactorial mechanisms including mutational changes in iron transporter proteins associated with FDC uptake, ampC gene overproduction, and mexAB-oprM overexpression. These findings highlight that a susceptibility testing to FDC must be performed prior to any prescription.


Asunto(s)
Antibacterianos , Infecciones por Pseudomonas , Humanos , Antibacterianos/farmacología , Antibacterianos/uso terapéutico , Antibacterianos/metabolismo , Pseudomonas aeruginosa , Cefalosporinas/farmacología , Cefalosporinas/uso terapéutico , beta-Lactamasas/metabolismo , Pruebas de Sensibilidad Microbiana , Infecciones por Pseudomonas/tratamiento farmacológico , Infecciones por Pseudomonas/microbiología , Cefiderocol
4.
Eur J Clin Microbiol Infect Dis ; 40(7): 1399-1404, 2021 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-33515094

RESUMEN

A recently developed, automated blood culture system and medium improve the time-to-positivity (TTP) for bacteremia. However, there have thus far been no genus-level analyses using this novel system. We evaluated and compared the changes in blood culture TTP between two systems: BacT/Alert 3D with a blood culture medium containing activated charcoal versus the more recent BacT/Alert Virtuo with a blood culture medium containing polymeric beads. This before-and-after study included blood cultures collected between July 2010 and April 2014 (3D, activated charcoal) and between July 2015 and April 2018 (Virtuo, polymeric beads). A total of 554,732 blood cultures were included, 267,935 (48.30%) during the first period and 286,797 (51.70%) during the second period. Overall, 55,611 (10.02%) tested positive for at least one microorganism. The incubation of the blood culture medium in the Virtuo system was associated with reduced TTP for the most prevalent bacteria, those representing 91.72% (n=51,006) of all the positive blood cultures. The median TTP was reduced by 0.99 h for Staphylococcus, Enterococcus, Streptococcus, Pseudomonadales, and most of the genera within the order Enterobacterales (except the family Morganellaceae). However, strictly anaerobic bacteria belonging to the genus Bacteroides, representing 0.85% (n=474) of all positive blood cultures, were detected 4.53 h later using the Virtuo system. Virtuo was associated with a shorter TTP for most bacteria, but this improvement was heterogeneous to the genus level.


Asunto(s)
Bacteriemia/diagnóstico , Cultivo de Sangre/métodos , Automatización , Bacterias/clasificación , Bacterias/aislamiento & purificación , Técnicas Bacteriológicas , Carbón Orgánico , Medios de Cultivo , Humanos , Microesferas , Factores de Tiempo
5.
Emerg Infect Dis ; 26(8): 1939-1941, 2020 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-32298228
6.
Crit Care ; 24(1): 611, 2020 10 15.
Artículo en Inglés | MEDLINE | ID: mdl-33076936

RESUMEN

BACKGROUND: Gut dysbiosis due to the adverse effects of antibiotics affects outcomes of lung infection. Previous murine models relied on significant depletion of both gut and lung microbiota, rendering the analysis of immune gut-lung cross-talk difficult. Here, we study the effects of antibiotic-induced gut dysbiosis without lung dysbiosis on lung immunity and the consequences on acute P. aeruginosa lung infection. METHODS: C57BL6 mice received 7 days oral vancomycin-colistin, followed by normal regimen or fecal microbial transplant or Fms-related tyrosine kinase 3 ligand (Flt3-Ligand) over 2 days, and then intra-nasal P. aeruginosa strain PAO1. Gut and lung microbiota were studied by next-generation sequencing, and lung infection outcomes were studied at 24 h. Effects of vancomycin-colistin on underlying immunity and bone marrow progenitors were studied in uninfected mice by flow cytometry in the lung, spleen, and bone marrow. RESULTS: Vancomycin-colistin administration induces widespread cellular immunosuppression in both the lung and spleen, decreases circulating hematopoietic cytokine Flt3-Ligand, and depresses dendritic cell bone marrow progenitors leading to worsening of P. aeruginosa lung infection outcomes (bacterial loads, lung injury, and survival). Reversal of these effects by fecal microbial transplant shows that these alterations are related to gut dysbiosis. Recombinant Flt3-Ligand reverses the effects of antibiotics on subsequent lung infection. CONCLUSIONS: These results show that gut dysbiosis strongly impairs monocyte/dendritic progenitors and lung immunity, worsening outcomes of P. aeruginosa lung infection. Treatment with a fecal microbial transplant or immune stimulation by Flt3-Ligand both restore lung cellular responses to and outcomes of P. aeruginosa following antibiotic-induced gut dysbiosis.


Asunto(s)
Antibacterianos/efectos adversos , Disbiosis/complicaciones , Terapia de Inmunosupresión/efectos adversos , Neumonía/etiología , Animales , Antibacterianos/farmacología , Modelos Animales de Enfermedad , Disbiosis/etiología , Disbiosis/fisiopatología , Terapia de Inmunosupresión/métodos , Pulmón/microbiología , Pulmón/fisiopatología , Ratones Endogámicos C57BL , Microbiota/efectos de los fármacos , Neumonía/fisiopatología , Pseudomonas aeruginosa/efectos de los fármacos , Vancomicina/efectos adversos , Vancomicina/farmacología
7.
Anaerobe ; 66: 102277, 2020 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-32987144

RESUMEN

Sneathia amnii is an opportunistic pathogen of the female reproductive tract that has been reported to cause infections during pregnancy and in the post-partum period. Infections outside the reproductive tract have rarely been described. We report the case of a spondylitis due to S. amnii in a 72-year old woman, successfully treated after seven weeks of antimicrobial therapy. Growth of this pathogen guided our diagnosis towards a gynecological pathology; we discovered an endometrium adenocarcinoma. This case emphasizes the need for adequate incubation of discal biopsies, using aerobic and anaerobic enrichment broth with prolonged incubation.


Asunto(s)
Antibacterianos/uso terapéutico , Fusobacterias/clasificación , Espondilitis/diagnóstico , Espondilitis/microbiología , Adenocarcinoma , Anciano , ADN Bacteriano , Neoplasias Endometriales , Femenino , Fusobacterias/efectos de los fármacos , Fusobacterias/aislamiento & purificación , Humanos , ARN Ribosómico 16S , Espondilitis/tratamiento farmacológico , Resultado del Tratamiento
8.
Anaerobe ; 63: 102202, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-32247000

RESUMEN

Clostridium spp. are recovered from 25% of the blood culture positive with anaerobes. However, the clinical relevance of Clostridium bacteremia has been controverted in the literature, particularly for C. perfringens. We aimed to evaluate the clinical relevance of Clostridium bacteremia, either due to C. perfringens or other Clostridium species, and to identify the risk factors of mortality in these patients. A retrospective cohort study was conducted from January 2010 to April 2018. All the patients with at least one blood culture positive with any Clostridium species were included. Eighty-one patients with a least one blood culture positive with any Clostridium species were included. Seventy patients (86.4%) fulfilled the criteria for clinically relevant bacteremia. Bacteremia due to C. perfringens tended to be less clinically relevant than other Clostridium species but this was not statistically significant (76% vs 91.2%, P = 0.09). In case of clinically relevant bacteremia, the 30-day mortality rate was 31.4%. In multivariate analysis, adequate empiric antimicrobial therapy was significantly associated with survival (P = 0.03). In conclusion, bacteremia due to C. perfringens or other Clostridium species is usually clinically relevant. This finding was also supported by an improved survival at 30 days when adequate empiric antimicrobial therapy was administered.


Asunto(s)
Bacteriemia , Infecciones por Clostridium , Clostridium/aislamiento & purificación , Adulto , Anciano , Antibacterianos/uso terapéutico , Bacteriemia/tratamiento farmacológico , Bacteriemia/epidemiología , Clostridium/efectos de los fármacos , Infecciones por Clostridium/tratamiento farmacológico , Infecciones por Clostridium/mortalidad , Clostridium perfringens/efectos de los fármacos , Clostridium perfringens/aislamiento & purificación , Estudios de Cohortes , Femenino , Humanos , Hipotermia/microbiología , Masculino , Persona de Mediana Edad , Mortalidad , Estudios Retrospectivos , Factores de Riesgo
9.
Artículo en Inglés | MEDLINE | ID: mdl-30962336

RESUMEN

While antibiotic use is a risk factor of carbapenemase-producing Enterobacteriaceae (CPE) acquisition, the importance of timing of antibiotic administration relative to CPE exposure remains unclear. In a murine model of gut colonization by New Delhi metallo-beta-lactamase-1 (NDM-1)-producing Klebsiella pneumoniae, a single injection of clindamycin within at most 1 week before or after CPE exposure induced colonization persisting up to 100 days. The timing of antibiotic administration relative to CPE exposure may be relevant to infection control and antimicrobial stewardship approaches.


Asunto(s)
Antibacterianos/administración & dosificación , Proteínas Bacterianas/metabolismo , Infecciones por Enterobacteriaceae/tratamiento farmacológico , Enterobacteriaceae/efectos de los fármacos , Microbioma Gastrointestinal/efectos de los fármacos , beta-Lactamasas/metabolismo , Animales , Modelos Animales de Enfermedad , Enterobacteriaceae/metabolismo , Control de Infecciones/métodos , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/metabolismo , Ratones , Pruebas de Sensibilidad Microbiana/métodos
11.
Anaerobe ; 59: 32-34, 2019 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-31103530

RESUMEN

Clostridium ventriculi (formerly Sarcina ventriculi) is a Gram-positive, obligate anaerobic coccus. Human infections due to this bacterium have rarely been reported, its involvement in the development of gastric ulcers and perforation has been suggested. We present a case of bacteremia due to C. ventriculi following acute colonic pseudo-obstruction.


Asunto(s)
Bacteriemia/diagnóstico , Bacteriemia/patología , Infecciones por Clostridium/diagnóstico , Infecciones por Clostridium/patología , Clostridium/aislamiento & purificación , Seudoobstrucción Colónica/complicaciones , Anciano , Bacteriemia/microbiología , Infecciones por Clostridium/microbiología , Humanos , Masculino
15.
Infection ; 45(4): 425-431, 2017 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-28120176

RESUMEN

PURPOSE: Two randomized controlled trials (RCTs) showed the non-inferiority of fidaxomicin compared with vancomycin for Clostridium difficile infection (CDI) treatment and its superiority regarding recurrence rate. The aim of this study was to evaluate fidaxomicin's efficacy in clinical practice. METHODS: This single-center prospective cohort study included hospitalized patients treated with fidaxomicin for CDI. Demographic, clinical and biological data were collected. Primary outcome was efficacy of fidaxomicin (clinical cure, recurrence and global cure) at 10 weeks. Secondary outcome was efficacy among different subgroups. RESULTS: Ninety-nine patients were included: 42 severe CDI, 16 complicated CDI and 41 recurrent CDI. Rates of clinical cure, recurrence and global cure were 87, 15 and 59%, respectively. Subgroup analysis showed a higher recurrence rate for patients with recurrent CDI compared with first episode (8 vs. 26%; p = 0.04). Binary toxin was associated with severe/complicated CDI (80 vs. 50%; p < 0.01) and recurrence (32 vs. 7%; p < 0.01). Fidaxomicin was used as a first line for 83% of the patients with recurrence and for only 52% of first episodes even though 86% had recurrence's risk factors. CONCLUSION: Compared with RCTs, fidaxomicin in real world is used for patients with more severe and recurrent CDI, but clinical cure and recurrence rates were similar. Comparative studies are needed in these specific subgroups. Our data also illustrate clinicians' difficulty to define a "patient at risk for recurrence" among the first episodes. Finally, we showed that binary toxin could be important in the screening for severity and recurrence risks.


Asunto(s)
Aminoglicósidos/uso terapéutico , Antibacterianos/uso terapéutico , Infecciones por Clostridium/tratamiento farmacológico , Anciano , Clostridioides difficile/efectos de los fármacos , Femenino , Fidaxomicina , Francia , Hospitales Universitarios , Humanos , Masculino , Persona de Mediana Edad , Estudios Prospectivos
18.
Crit Care ; 19: 30, 2015 Feb 02.
Artículo en Inglés | MEDLINE | ID: mdl-25641219

RESUMEN

INTRODUCTION: The primary objective of this study was to determine the efficiency of hydrogen peroxide (H2O2) techniques in disinfection of ICU rooms contaminated with multidrug-resistant organisms (MDRO) after patient discharge. Secondary objectives included comparison of the efficiency of a vaporizator (HPV, Bioquell) and an aerosolizer using H2O2, and peracetic acid (aHPP, Anios) in MDRO environmental disinfection, and assessment of toxicity of these techniques. METHODS: This prospective cross-over study was conducted in five medical and surgical ICUs located in one University hospital, during a 12-week period. Routine terminal cleaning was followed by H2O2 disinfection. A total of 24 environmental bacteriological samplings were collected per room, from eight frequently touched surfaces, at three time-points: after patient discharge (T0), after terminal cleaning (T1) and after H2O2 disinfection (T2). RESULTS: In total 182 rooms were studied, including 89 (49%) disinfected with aHPP and 93 (51%) with HPV. At T0, 15/182 (8%) rooms were contaminated with at least 1 MDRO (extended spectrum ß-lactamase-producing Gram-negative bacilli 50%, imipenem resistant Acinetobacter baumannii 29%, methicillin-resistant Staphylococcus aureus 17%, and Pseudomonas aeruginosa resistant to ceftazidime or imipenem 4%). Routine terminal cleaning reduced environmental bacterial load (P <0.001) without efficiency on MDRO (15/182 (8%) rooms at T0 versus 11/182 (6%) at T1; P = 0.371). H2O2 technologies were efficient for environmental MDRO decontamination (6% of rooms contaminated with MDRO at T1 versus 0.5% at T2, P = 0.004). Patient characteristics were similar in aHPP and HPV groups. No significant difference was found between aHPP and HPV regarding the rate of rooms contaminated with MDRO at T2 (P = 0.313). 42% of room occupants were MDRO carriers. The highest rate of rooms contaminated with MDRO was found in rooms where patients stayed for a longer period of time, and where a patient with MDRO was hospitalized. The residual concentration of H2O2 appears to be higher using aHPP, compared with HPV. CONCLUSIONS: H2O2 treatment is efficient in reducing MDRO contaminated rooms in the ICU. No significant difference was found between aHPP and HPV regarding their disinfection efficiency.


Asunto(s)
Infección Hospitalaria/prevención & control , Desinfectantes/farmacología , Desinfección/instrumentación , Eficiencia , Peróxido de Hidrógeno/farmacología , Unidades de Cuidados Intensivos/normas , Volatilización , Estudios Cruzados , Desinfectantes/uso terapéutico , Desinfección/métodos , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Peróxido de Hidrógeno/uso terapéutico , Habitaciones de Pacientes/normas , Ácido Peracético/farmacología , Ácido Peracético/uso terapéutico , Estudios Prospectivos
20.
Nat Commun ; 14(1): 78, 2023 01 05.
Artículo en Inglés | MEDLINE | ID: mdl-36604442

RESUMEN

Carbapenemase-producing Enterobacterales (CPE) are spreading rapidly in hospital settings. Asymptomatic CPE gut colonisation may be associated with dysbiosis and gut-lung axis alterations, which could impact lung infection outcomes. In this study, in male C57BL/6JRj mice colonised by CPE, we characterise the resulting gut dysbiosis, and analyse the lung immune responses and outcomes of subsequent Pseudomonas aeruginosa lung infection. Asymptomatic gut colonisation by CPE leads to a specific gut dysbiosis and increases the severity of P. aeruginosa lung infection through lower numbers of alveolar macrophages and conventional dendritic cells. CPE-associated dysbiosis is characterised by a near disappearance of the Muribaculaceae family and lower levels of short-chain fatty acids. Faecal microbiota transplantation restores immune responses and outcomes of lung infection outcomes, demonstrating the involvement of CPE colonisation-induced gut dysbiosis in altering the immune gut-lung axis, possibly mediated by microbial metabolites such as short-chain fatty acids.


Asunto(s)
Infecciones por Pseudomonas , Pseudomonas aeruginosa , Animales , Ratones , Masculino , Klebsiella pneumoniae , Disbiosis , Ratones Endogámicos C57BL , Pulmón , Ácidos Grasos Volátiles
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA